Free Trial

Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal

Virios Therapeutics stock price

Key Points

  • Virios is a developmental-stage biotech developing treatments for fibromyalgia.
  • There is no cure for fibromyalgia, only treatments to manage the symptoms.
  • Virios received positive FDA feedback on its IMC-1 Phase 3 program proposal.
  • IMC-1 has been designated fast-track status, and the toxicology report will be submitted to FDA in May.
  • Shares gapped over 75% and surpassed 79 million shares of volume.
  • 5 stocks we like better than Virios Therapeutics

Virios Therapeutics Inc. NASDAQ: VIRI is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune response-triggered maladies. The company went public in December 2020. Shares reached a high of $16.71 before making their painful trek to a low of $0.22 a year later in December 2021. Its core product is IMC-1 to treat fibromyalgia symptoms.

IMC-2 is a long-COVID treatment using a proprietary blend of valacyclovir and celecoxib. On Sept. 20, 2022, Virios shocked investors with a $5 million secondary offering at $0.50 in September 2022. Shares have been staging a rally preceding the 75% gap on news that the FDA accepted its Phase 3 clinical trial proposal for IMC-1. Many large pharmaceutical companies are currently working on fibromyalgia treatments, including Pfizer Inc. NYSE: PFE, Eli Lilly & Co. NYSE: LLY and Allergan plc NYSE: AGN.

What is Fibromyalgia?

Fibromyalgia is an elusive diagnosis that can only be identified based on many symptoms. It’s been described as a long-term autoimmune disorder caused by abnormalities in how the central nervous system processes pain signals. The main symptoms are widespread chronic and continuous pain in four or more body areas accompanied by flu-like fatigue, exhaustion, mood and memory issues. It affects the muscles, tendons, bones and joints. The pain can be an ache, sharp stabbing, or burning sensation. It’s a cyclical disorder where the pain is continuous but fluctuates in intensity.


The constant pain gives the rest of the body a heightened sensitivity to pain. This can lead to other related conditions like hyperalgesia, making you extremely sensitive to pain, or allodynia, where you feel physical pain from things that shouldn't cause pain, like bright lights, food, and smoke. Other symptoms can range from irritable bowel syndrome, and insomnia to anxiety, tension, headaches and depression.

Current Treatments

There is no cure for fibromyalgia and no diagnostic tests for it. The exact cause is also unknown. There are only treatments to help manage the symptoms. There are over 3.5 million diagnosed fibromyalgia patients in the U.S. and an estimated 3% to 5% of the global population. There may be many more, as no diagnostic test definitively detects it. Various testing methods involve a process of elimination ruling out other diagnoses like thyroid disorders, lupus or rheumatoid arthritis. Various tests include blood and urine and possible x-rays and other scans.

Virios Therapeutics IMC-1

While there is no cure or diagnosis for fibromyalgia, Virios believes that herpes simplex virus type-1  (HSV-1) is key in triggering the symptoms. HSV-1 is a highly contagious virus that causes cold cores, oral herpes and fever blisters. IMC-1 is a proprietary formulation of celecoxib and famciclovir; both are currently FDA-approved drugs. IMC-1 is designed to stop viral replication of the HSV-1 virus. The phase 2 clinical trial produced a statistically significant reduction in fibromyalgia patients.

IMC-1 Phase 2B Mixed Results

It’s worth noting that its fibromyalgia outcome research trial evaluating synergistic suppression of HSV-1 (FORTRESS) Phase 2B trial didn’t meet statistical significance for its primary efficacy endpoint during the first half of the trial This was during the delta variant strain period of COVID-19. However, during the second half of the trial, patients indicated statistical improvement in the primary pain reduction point at week 14. Based on new fibromyalgia patients who didn't participate in prior clinical trials and treatment, it demonstrated clinically and significantly significant in reducing fibromyalgia symptoms.

FDA Feedback and Awaiting Phase 3 Trials

The company went to the FDA proposing Phase 3 clinical trials targeting "community-based fibromyalgia patients" who haven't participated in prior trials or treatments. The FDA accepted it, but it is subject to review of final toxicology reports, which Virios will submit in May 2023. Investors will have to wait for the FDA to approve the commencement of the Phase 3 trial and await results and FDA approval afterward. The company has $7 million in cash left to fund operations until mid-2024. Further funding may result in another secondary offering, so investors should be cautious of gaps preceding financing announcements.  

 

Virios Therapeutics stock chart

Daily Gap and Fill or Crap

The daily candlestick chart of VIRI indicates a heavy volume gap in the FDA acceptance news. What remains if whether VIRI will continue to rise to fill the gap at $3.15 or crap and fall back to the $0.61 daily market structure high (MSH) sell trigger. The daily 20-period exponential moving average (EMA) rises to $0.60, followed by the daily 50-period MA at $0.42. The daily stochastic is chopping flat at the overbought 80-band. Pullback support levels are at $0.78, $0.70, $0.61 and $0.51.

 

→ Nvidia’s Quiet $1 Trillion Pivot (From Weiss Ratings) (Ad)

Should you invest $1,000 in Virios Therapeutics right now?

Before you consider Virios Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Virios Therapeutics wasn't on the list.

While Virios Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Virios Therapeutics (VIRI)
0.28 of 5 stars
$0.21+17.0%N/A-0.78N/A
Allergan (AGN)
0 of 5 stars
$193.02flat1.53%-12.07N/A
Eli Lilly and Company (LLY)
4.823 of 5 stars
$807.43-0.1%0.64%118.91Moderate Buy$769.53
Pfizer (PFE)
4.7591 of 5 stars
$28.88+0.7%5.82%-481.25Hold$35.86
GAP (GPS)
3.7047 of 5 stars
$20.98+0.6%2.86%15.66Hold$21.15
Compare These Stocks  Add These Stocks to My Watchlist 

Jea Yu

About Jea Yu

  • JeaYu21@gmail.com

Contributing Author

Trading Strategies

Experience

Jea Yu has been a contributing writer for MarketBeat since 2018.

Areas of Expertise

Equities, options, ETFs and futures; fundamental, qualitative, quantitative and technical analysis and pattern identification; active and swing trading; trading systems and methodology development

Education

Bachelor of Arts, University of Maryland, College Park

Past Experience

U.S. equity markets trader, writer and analyst for over 25 years. Published four books by publishers McGraw-Hill, John Wiley & Sons, Marketplace Books and Bloomberg Press. Speaker at various expos and seminars and has been quoted and featured in USA Today, The Wall Street Journal, Traders Magazine, The Financial Times and various trade publications, including Stocks & Commodities, Active Trader and Online Investor.


Featured Articles and Offers

Search Headlines: